Life

Briefing: Deaths and Health Care Issues in ICE Detention Centers Under the Second Trump Administration

Strategic angle: An overview of deaths in ICE custody and health care issues during the Trump administration.

Briefing: STAT+: Eli Lilly and the ‘societal obligation’ of GLP-1s

Strategic angle: Eli Lilly discusses the 'societal obligation' of GLP-1s amidst other biotech news.

Briefing: Merck to Acquire Terns Pharmaceuticals for $6.7 Billion

Strategic angle: The acquisition aims to enhance Merck's portfolio with a promising leukemia treatment.

Briefing: How to make emergency rooms safer for people with dementia

Strategic angle: A federal vaccine adviser departs ACIP, adults turn to AI chatbots for health info, and radiologists sift through deepfake X-rays.

Briefing: Federal vaccine adviser departs ACIP

Strategic angle: Robert Malone, an outspoken doctor and ally of RFK Jr., is stepping away from a panel of federal vaccine advisers after a federal judge blocked the panel’s work.

Briefing: The Status of Abortion-related State Ballot Initiatives Since Dobbs

Strategic angle: Since the Supreme Court’s Dobbs decision, voters in 17 states have weighed in on ballot measures regarding abortion.

Briefing: Opinion: We’re launching a new CMS pilot program to help children with complex conditions

Strategic angle: CMS aims to transform fragmented care into a cohesive system for children with complex health needs.

Briefing: FTC Strikes Proposed Deal with CVS Over Insulin Price Manipulation

Strategic angle: Settlement expected to save Americans up to $7 billion in out-of-pocket costs over the next decade.

Briefing: Drug company penalties for paying kickbacks to doctors failed to dent bottom lines, analysis finds

Strategic angle: An analysis reveals that drugmakers penalized for kickbacks paid only a small fraction of their U.S. revenue from the drugs involved.

Briefing: FDA slams Soon-Shiong and ImmunityBio for making ‘false and misleading’ claims about a drug

Strategic angle: Patrick Soon-Shiong, a controversial figure in the biotech industry, was accused by the FDA of making false and misleading claims about a cancer treatment.

Briefing: STAT+: How will Trump handle the CDC and ACIP?

Strategic angle: Trump's decisions serve as a test of how much sway RFK Jr.'s MAHA movement still has in the White House.

Briefing: Claims Denials and Appeals in ACA Marketplace Plans in 2024

Strategic angle: An analysis of claims denials and appeals reveals significant challenges for consumers in the ACA Marketplace.

Briefing: Can you spot a deepfake X-ray? Neither can your radiologist

Strategic angle: Deepfake images can mislead viewers, upend elections, and instigate violence. They can also, researchers say, disrupt medical care.

Briefing: Buzzy AI doctor startup raises funds, will meet FDA

Strategic angle: In this edition of STAT Health Tech: AI doctor startup raises fresh capital, and what Medicare chief Chris Klomp said at STAT Summit.

Briefing: What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid

Strategic angle: This brief describes current coverage of GLP-1s in Medicare and Medicaid, and CMS's efforts to expand access and lower costs through the BALANCE model.

Briefing: Gilead to acquire immunology biotech, offers lifeline to Galapagos

Strategic angle: In today's Readout newsletter: Gilead to acquire an immunology biotech and Merck partners with Flagship company on IBD targets.

Briefing: Pharmalittle: Trump Drug Pricing Flaw and Gilead Deal Insights

Strategic angle: Comments from a top Trump administration health official highlight significant issues in the president’s drug pricing plans.

Briefing: Opinion: Every pandemic is followed by amnesia. But Covid’s is very different

Strategic angle: In this excerpt from their new book “Whiplash,” David Blumenthal and James A. Morone describe how scientists became villains to MAGA.

Briefing: The potential loophole in Trump’s plan to get other countries to pay more for drugs

Strategic angle: Diverging messages on the main effort to address U.S. drug prices point to a loophole in Trump's plan.

Briefing: What growing up in an end-times church taught a science communicator about dispelling misinformation

Strategic angle: A passion for snakes opened a crack in the religious beliefs science communicator Paul Martin Jensen grew up with in a end-times Pentecostal church.